Single Center Study Evaluating The Effects Of N-803 Stimulation On The Expansion, Enrichment, And Proliferation Of Natural Killer Cells Collected By Apheresis
Latest Information Update: 30 Sep 2024
At a glance
- Drugs Nogapendekin alfa inbakicept (Primary)
- Indications Acute myeloid leukaemia; Bladder cancer; Cervical cancer; Colorectal cancer; Gastric cancer; Haematological malignancies; Hereditary nonpolyposis colorectal cancer; HIV infections; HIV-1 infections; Liver cancer; Malignant melanoma; Merkel cell carcinoma; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
- Focus Adverse reactions
- Sponsors ImmunityBio
Most Recent Events
- 20 Sep 2024 Status changed from recruiting to completed.
- 26 Sep 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Jun 2024.
- 26 Sep 2023 Status changed from not yet recruiting to recruiting.